IKT - Inhibikase Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
12,371
12,035
11,359
893.802
2,553
Selling general and administrative
6,526
6,217
6,508
2,623
4,268
Total operating expenses
18,835
18,129
14,766
2,818
5,698
Operating income or loss
-18,835
-18,129
-14,766
-2,818
-5,698
Interest expense
0.163
-
19.923
29.402
24.835
Income before tax
-18,817
-18,054
-14,786
-2,848
-5,723
Income from continuing operations
-18,817
-18,054
-14,786
-2,848
-5,723
Net income
-18,817
-18,054
-14,786
-2,848
-5,723
Net income available to common shareholders
-18,817
-18,054
-14,786
-2,848
-5,723
Basic EPS
-
-0.72
-0.81
-0.35
-0.57
Diluted EPS
-
-0.72
-0.81
-0.35
-0.57
Basic average shares
-
25,212
18,209
8,213
10,032
Diluted average shares
-
25,212
18,209
8,213
10,032
EBITDA
-
-18,122
-14,766
-2,818
-5,698